Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

155.40 -0.07 (-0.05%)
Streaming Delayed Price Updated: 12:58 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come. 
Via Investor's Business Daily
AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate
 
Via Benzinga
The 5 Best Dividend Stocks to Buy Now
These are the best dividend stocks to invest in now. Companies with reliable payouts and a strong track record make great investments. 
Via InvestorPlace
7 Retirement Stocks for Steady Long-Term Income Growth
Investors looking for retirement stocks should look for companies with high growth and steady income and shun risky, unproven stocks. 
Via InvestorPlace
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year
 
Via Benzinga
Looking At AbbVie's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades. 
Via Benzinga
AbbVie Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades. 
Via Benzinga
7 Profitable Places to Hide Your Money During a Bear Market
With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification. 
Via InvestorPlace
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
The Top 10 Stocks Helping Warren Buffett Beat the Market
These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. All are generating solid returns in 2022. 
Via InvestorPlace
AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance
 
Via Benzinga
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
 
Via Benzinga
6 Undervalued Stocks You Should Buy For the Long Term
These six undervalued stocks have strong dividend and buyback programs and trade a very reasonable price-to-earnings multiples. 
Via InvestorPlace
4 Top Stock Trades for Wednesday: TSLA, PANW, SOFI, ABBV
Tesla, Palo Alto Networks, SoFi and AbbVie were our top stock trades for Wednesday. Let's look at how the charts are setting up. 
Via InvestorPlace
Tuesday Talk: The Rough Ride Continues
At the moment there seems to be no respite on the ride down, markets opened the week on Monday, by closing markedly down again. Market futures are still up heading into the open. 
Via Talk Markets
Let Dividend Stocks Protect You From The Bear Market
The market has been brutal in 2022, especially over the past couple of months. 
Via Talk Markets
7 Defensive Dividend Healthcare Stocks to Buy Now
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. 
Via InvestorPlace
10 Of The Highest Volume Options Contracts On Thursday
Trading volume is critical for small-window options traders, as it gives insight into how many contracts have been purchased on an options strike. A high-volume option can provide liquidity, giving... 
Via Benzinga
7 Stocks Moved By Traders On 'Fast Money: Halftime Report'
CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The... 
Via Benzinga
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
4 Healthcare Funds With "Double Discounts"
There's nothing that closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount plus a much bigger dividend. Let's take a look... 
Via Talk Markets
U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) . 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
Why Is GTY Technology (GTYH) Stock Up 100% Today?
GTY Technology (GTYH) stock is skyrocketing on Friday after the cloud software solutions company revealed a major deal with GI Partners. 
Via InvestorPlace
Why Is AbbVie Stock Down Today?
AbbVie (ABBV) stock is slipping on Friday following the release of the biopharmaceutical company's earnings report for Q1 2022. 
Via InvestorPlace
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.